Zanchi Anne, Perregaux Christine, Maillard Marc, Cefai Daniel, Nussberger Juerg, Burnier Michel
Division of Nephrology, Dept. of Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.
Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1228-34. doi: 10.1152/ajpendo.00171.2006. Epub 2006 Jul 11.
Glitazones are efficient insulin sensitizers that blunt the effects of angiotensin II (ANG II) in the rat. Sodium chloride is another important modulator of the systemic and renal effects of ANG II. Whether glitazones interfere with the interaction between sodium and the response to ANG II is not known. Therefore, we investigated the effects of pioglitazone on the relationship between sodium and the systemic and renal effects of ANG II in rats. Pioglitazone, or vehicle, was administered for 4 wk to 8-wk-old obese Zucker rats. Animals were fed a normal-sodium (NS) or a high-sodium (HS) diet. Intravenous glucose tolerance tests, systemic and renal hemodynamic responses to ANG II, and the renal ANG II binding and expression of ANG II type 1 (AT(1)) receptors were measured. The results of our study were that food intake and body weight increased, whereas blood pressure, heart rate, filtration fraction, and insulin levels decreased significantly with pioglitazone in obese rats on both diets. Pioglitazone blunted the systemic response to ANG II and abolished the increased responsiveness to ANG II induced by a HS diet. Pioglitazone modified the renal hemodynamic response to changes in salt intake while maintaining a lower filtration fraction with ANG II perfusion. These effects were associated with a decrease in the number and expression of the AT(1) receptor in the kidney. In conclusion, these data demonstrate that the peroxisome proliferator-activated receptor-gamma agonist pioglitazone modifies the physiological relationship between sodium chloride and the response to ANG II in insulin-resistant rats.
噻唑烷二酮类药物是有效的胰岛素增敏剂,可减弱大鼠体内血管紧张素II(ANG II)的作用。氯化钠是ANG II全身和肾脏效应的另一个重要调节因子。噻唑烷二酮类药物是否会干扰钠与ANG II反应之间的相互作用尚不清楚。因此,我们研究了吡格列酮对大鼠体内钠与ANG II全身和肾脏效应之间关系的影响。将吡格列酮或赋形剂给予8周龄的肥胖Zucker大鼠,持续4周。动物分别喂食正常钠(NS)或高钠(HS)饮食。测量静脉葡萄糖耐量试验、对ANG II的全身和肾脏血流动力学反应以及肾脏ANG II结合和1型ANG II(AT(1))受体的表达。我们的研究结果表明,两种饮食的肥胖大鼠服用吡格列酮后,食物摄入量和体重增加,而血压、心率、滤过分数和胰岛素水平显著降低。吡格列酮减弱了对ANG II的全身反应,并消除了高钠饮食诱导的对ANG II反应性增加。吡格列酮改变了肾脏对盐摄入量变化的血流动力学反应,同时在ANG II灌注时保持较低的滤过分数。这些效应与肾脏中AT(1)受体数量和表达的减少有关。总之,这些数据表明,过氧化物酶体增殖物激活受体γ激动剂吡格列酮改变了胰岛素抵抗大鼠体内氯化钠与ANG II反应之间的生理关系。